» Articles » PMID: 37751078

Discordance of Oncotype DX Scores in Synchronous Bilateral and Unilateral Multifocal Breast Cancers

Overview
Specialty Oncology
Date 2023 Sep 26
PMID 37751078
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Oncotype DX, a 21-gene expression profiling test, has become standard of care in the management of estrogen receptor (ER)-positive breast cancer. In multifocal tumors, it is unclear whether testing of the different foci is necessary. We evaluated the concordance of Oncotype DX recurrence scores (RS) between 2 tumor foci in synchronous bilateral or unilateral multifocal tumors and characterized pathological predictors of discordance.

Methods: We reviewed 713 ER+, HER2- primary invasive breast cancer patients with Oncotype RS and identified 17 bilateral synchronous patients (34 tumors) and 13 unilateral multifocal patients (26 tumors) with available Oncotype RS on all foci. Discordance in Oncotype RS between synchronous tumors was recorded and associations with clinicopathologic features including tumor size, histology, Nottingham histologic grade, progesterone receptor staining, and Ki67 index were analyzed.

Results: Bilateral synchronous tumors were present in older patients (median age 59 years) and had larger tumor (median size 17 mm) and more discordant histology (10/17, 59%) as compared to unilateral multifocal tumors (median age 49 years, p < 0.01; median tumor size 12 mm, p = 0.01; discordant histology 2/13, 15%, p = 0.03). Oncotype RS were discordant in 47% (8/17) of bilateral and 54% (7/13) of unilateral multifocal tumors. Concordant Oncotype RS was associated with similar histologic grade and Ki67 index in 78% (7/9) of bilateral and 100% (6/6) of multifocal tumors. In contrast, only 25% (2/8) of bilateral (p = 0.06) and 14% (1/7) of unilateral multifocal (p < 0.01) cases with discordant Oncotype RS had concordant histology grades and Ki67 levels. In synchronous tumors with discordant Oncotype RS and Ki67 index, all (4/4) foci with higher RS had higher Ki67 index.

Conclusion: Discordance of Oncotype RS is common in both bilateral and unilateral multifocal breast cancer and is likely associated with discordant histologic grade or Ki67.

Citing Articles

Impact of Molecular Profiling on Therapy Management in Breast Cancer.

Ultimescu F, Hudita A, Popa D, Olinca M, Muresean H, Ceausu M J Clin Med. 2024; 13(17).

PMID: 39274207 PMC: 11396537. DOI: 10.3390/jcm13174995.

References
1.
Albain K, Barlow W, Shak S, Hortobagyi G, Livingston R, Yeh I . Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2009; 11(1):55-65. PMC: 3058239. DOI: 10.1016/S1470-2045(09)70314-6. View

2.
Sparano J, Gray R, Makower D, Pritchard K, Albain K, Hayes D . Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. N Engl J Med. 2015; 373(21):2005-14. PMC: 4701034. DOI: 10.1056/NEJMoa1510764. View

3.
Toi M, Iwata H, Yamanaka T, Masuda N, Ohno S, Nakamura S . Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population. Cancer. 2010; 116(13):3112-8. DOI: 10.1002/cncr.25206. View

4.
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

5.
Paik S, Tang G, Shak S, Kim C, Baker J, Kim W . Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006; 24(23):3726-34. DOI: 10.1200/JCO.2005.04.7985. View